$33.26 million market cap$33.26 million market cap.
$12.5 million cash.
That nets to $20.6 million for the business itself.
That's $5.15 million for the base business that produced $6.6 million cash last year.
$5.15 million for the avenanthramide clinical trial about to begin in the next ~30 days.
$5.15 million for the fibrosis drug before a go / no go clinical trial decision in the summer.
$5.15 million for PGX and its broader opportunities.